Search details
1.
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
N Engl J Med
; 388(17): 1547-1558, 2023 Apr 27.
Article
in English
| MEDLINE | ID: mdl-36912538
2.
Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial.
JAMA
; 331(17): 1460-1470, 2024 05 07.
Article
in English
| MEDLINE | ID: mdl-38581198
3.
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
BMC Health Serv Res
; 23(1): 610, 2023 Jun 09.
Article
in English
| MEDLINE | ID: mdl-37296430
4.
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).
BJU Int
; 130(3): 370-380, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35373443
5.
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer.
Br J Cancer
; 123(7): 1063-1070, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32669672
6.
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen.
Cancer Causes Control
; 31(5): 431-449, 2020 May.
Article
in English
| MEDLINE | ID: mdl-32162172
7.
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
BJU Int
; 125(4): 506-514, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31900963
8.
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.
N Engl J Med
; 375(15): 1415-1424, 2016 10 13.
Article
in English
| MEDLINE | ID: mdl-27626136
9.
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
JAMA
; 319(9): 883-895, 2018 03 06.
Article
in English
| MEDLINE | ID: mdl-29509864
10.
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee.
Br J Cancer
; 115(1): 90-4, 2016 Jun 28.
Article
in English
| MEDLINE | ID: mdl-27253172
11.
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?
Cancer Causes Control
; 27(12): 1465-1474, 2016 Dec.
Article
in English
| MEDLINE | ID: mdl-27830401
12.
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer).
BMC Med Res Methodol
; 15: 6, 2015 Jan 23.
Article
in English
| MEDLINE | ID: mdl-25613468
13.
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.
Lancet Oncol
; 15(10): 1109-18, 2014 Sep.
Article
in English
| MEDLINE | ID: mdl-25163905
14.
"Let's get the best quality research we can": public awareness and acceptance of consent to use existing data in health research: a systematic review and qualitative study.
BMC Med Res Methodol
; 13: 72, 2013 Jun 04.
Article
in English
| MEDLINE | ID: mdl-23734773
15.
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment.
NEJM Evid
; 2(4): EVIDoa2300018, 2023 Apr.
Article
in English
| MEDLINE | ID: mdl-38320051
16.
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial.
Pharmacoeconomics
; 40(12): 1207-1220, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36201131
17.
Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testing.
J Med Screen
; 29(4): 268-271, 2022 12.
Article
in English
| MEDLINE | ID: mdl-36062629
18.
Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study).
Int J Cancer
; 128(2): 440-6, 2011 Jan 15.
Article
in English
| MEDLINE | ID: mdl-20473853
19.
Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities.
BJU Int
; 108(9): 1402-8, 2011 Nov.
Article
in English
| MEDLINE | ID: mdl-21481132
20.
The Saccharomyces cerevisiae anaphase-promoting complex interacts with multiple histone-modifying enzymes to regulate cell cycle progression.
Eukaryot Cell
; 9(10): 1418-31, 2010 Oct.
Article
in English
| MEDLINE | ID: mdl-20709786